ID30339A - Metode pengobatan baru - Google Patents

Metode pengobatan baru

Info

Publication number
ID30339A
ID30339A IDW00200102237A ID20012237A ID30339A ID 30339 A ID30339 A ID 30339A ID W00200102237 A IDW00200102237 A ID W00200102237A ID 20012237 A ID20012237 A ID 20012237A ID 30339 A ID30339 A ID 30339A
Authority
ID
Indonesia
Prior art keywords
treatment method
new treatment
new
treatment
Prior art date
Application number
IDW00200102237A
Other languages
English (en)
Indonesian (id)
Inventor
Colin Houston Dr Macphee
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of ID30339A publication Critical patent/ID30339A/id

Links

Classifications

    • G—PHYSICS
    • G11—INFORMATION STORAGE
    • G11B—INFORMATION STORAGE BASED ON RELATIVE MOVEMENT BETWEEN RECORD CARRIER AND TRANSDUCER
    • G11B20/00—Signal processing not specific to the method of recording or reproducing; Circuits therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • AIDS & HIV (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
IDW00200102237A 1999-04-15 2000-04-17 Metode pengobatan baru ID30339A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9908647.2A GB9908647D0 (en) 1999-04-15 1999-04-15 Novel compounds

Publications (1)

Publication Number Publication Date
ID30339A true ID30339A (id) 2001-11-22

Family

ID=10851605

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW00200102237A ID30339A (id) 1999-04-15 2000-04-17 Metode pengobatan baru

Country Status (32)

Country Link
EP (2) EP1274407B1 (de)
JP (1) JP2003516310A (de)
KR (1) KR20010108506A (de)
CN (1) CN1413105A (de)
AP (1) AP2001002291A0 (de)
AT (1) ATE319437T1 (de)
AU (1) AU4583000A (de)
BG (1) BG106104A (de)
BR (1) BR0009776A (de)
CA (1) CA2370127A1 (de)
CZ (1) CZ20013688A3 (de)
DE (1) DE60026508T2 (de)
DK (1) DK1274407T3 (de)
DZ (1) DZ3151A1 (de)
EA (1) EA200101089A1 (de)
ES (1) ES2256003T3 (de)
GB (1) GB9908647D0 (de)
HK (1) HK1053788A1 (de)
HR (1) HRP20010746A2 (de)
HU (1) HUP0300479A2 (de)
ID (1) ID30339A (de)
IL (1) IL145875A0 (de)
MA (1) MA25351A1 (de)
MX (1) MXPA01010428A (de)
NO (1) NO20014950L (de)
PL (1) PL364720A1 (de)
PT (1) PT1274407E (de)
SK (1) SK14532001A3 (de)
TR (1) TR200102977T2 (de)
WO (1) WO2000062766A2 (de)
YU (1) YU77901A (de)
ZA (1) ZA200108446B (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9913782D0 (en) * 1999-06-14 1999-08-11 Smithkline Beecham Plc Novel compounds
EP1331934B1 (de) * 2000-11-09 2006-03-29 Phenion GmbH & Co KG Ppar-alpha,beta-aktivatoren zur behandlung von alopecia areata und vitiligo
GB0030845D0 (en) * 2000-12-18 2001-01-31 Smithkline Beecham Plc Novel treatment
GB2373725A (en) * 2001-03-30 2002-10-02 Novartis Ag Use of a PPAR gamma agonist in the production of a medicament for the prevention or treatment of diseases associated with IL-10 production
US20060013775A1 (en) * 2001-11-26 2006-01-19 Gristwood Robert W Use of ppar activators for the treatment of pulmonary fibrosis
DE10204398A1 (de) * 2002-02-04 2003-08-14 Univ Goettingen Georg August Neue Verwendung von Liganden der 'Peroxisome Proliferator-Activated receptors'(PPAR)
US8293479B2 (en) 2002-05-02 2012-10-23 Los Angeles Biomedical Research Institute At Harbor Ucla Medical Center Use of parathyroid hormone-related protein(PTHRP) in the diagnosis and treatment of chronic lung disease and other pathologies
US6992093B2 (en) 2002-05-02 2006-01-31 Los Angeles Biomedical Research Institute At Harbor Ucla Medical Center Method of inhibiting lipofibroblast to myofibroblast transdifferentiation
US20030220300A1 (en) * 2002-05-14 2003-11-27 Hwang Cheng Shine Reduction of hair growth
ITRM20050389A1 (it) 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
KR101333089B1 (ko) 2006-05-22 2013-11-27 재단법인 아산사회복지재단 로지글리타존을 유효성분으로 함유하는 흡연-유발 만성폐쇄성 폐질환 예방 또는 치료용 약제학적 조성물
GB0913672D0 (en) 2009-08-05 2009-09-16 Argenta Discovery Ltd Glitazones
EP2222272B1 (de) * 2008-08-07 2012-11-07 Pulmagen Therapeutics (Inflammation) Limited Behandlung von Atemwegserkrankungen
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
UA107562C2 (uk) 2008-12-05 2015-01-26 Спосіб лікування псоріазу
PL2379507T3 (pl) 2008-12-30 2014-03-31 Pulmagen Therapeutics Inflammation Ltd Związki sulfonamidu do leczenia zaburzeń układu oddechowego
EA020856B1 (ru) 2009-02-16 2015-02-27 Джулиани Интернэшнл Лимитед Способы лечения патологических состояний, связанных с волосами
WO2010150014A1 (en) 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment
WO2011098746A1 (en) 2010-02-09 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
GB201002243D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
GB201002224D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
JP6301844B2 (ja) 2012-02-09 2018-03-28 ノグラ ファーマ リミテッド 線維症の処置方法
EP2844242A1 (de) 2012-04-18 2015-03-11 Nogra Pharma Limited Verfahren zur behandlung lactoseintoleranz
CN107073079A (zh) * 2014-09-08 2017-08-18 达纳-法伯癌症研究所公司 包括给予PPAR‑γ激动剂的治疗癌症的方法
CA3049856C (en) * 2017-01-13 2021-10-26 Tobishi Pharmaceutical Co., Ltd. Neutrophil activation regulator
EP3921299B1 (de) 2019-02-08 2024-11-20 Nogra Pharma Limited Verfahren zur herstellung von 3-(4'-aminophenyl)-2-methoxypropionsäure, sowie analoge und zwischenprodukte davon
JP2020145939A (ja) * 2019-03-12 2020-09-17 日本製粉株式会社 アレルギー性鼻炎抑制用組成物
CN116531374A (zh) * 2023-04-20 2023-08-04 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) 吡格列酮及其盐在制备用于治疗系统性红斑狼疮的产品中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9611947D0 (en) * 1996-06-07 1996-08-07 Glaxo Group Ltd Medicaments
JPH10139665A (ja) * 1996-09-12 1998-05-26 Sankyo Co Ltd トログリタゾンを含有するグルタチオン還元酵素活性増強剤
DE69726182T2 (de) * 1996-12-11 2004-08-12 Dana-Farber Cancer Institute, Inc., Boston Methoden und pharmazeutische zusammenstellungen zur wachstumsverhinderung von tumorzellen enthaltend einen ppar-gamma agonisten und einen map kinase inhibitor
EP0963199A1 (de) * 1996-12-31 1999-12-15 The Salk Institute For Biological Studies Behandlung von krankheitszuständen die durch vermehrung von neoplastischen zellen entstehen durch ppar-gamma aktivatoren und zusammenstellungen die dazu nützlich sind
FR2773075B1 (fr) * 1997-12-31 2000-05-05 Cird Galderma Utilisation d'activateurs de ppar-gamma en dermatologie
US6028088A (en) * 1998-10-30 2000-02-22 The University Of Mississippi Flavonoid derivatives

Also Published As

Publication number Publication date
NO20014950D0 (no) 2001-10-11
PT1274407E (pt) 2006-06-30
EP1274407B1 (de) 2006-03-08
JP2003516310A (ja) 2003-05-13
ATE319437T1 (de) 2006-03-15
GB9908647D0 (en) 1999-06-09
MXPA01010428A (es) 2002-05-06
EP1593379A3 (de) 2007-10-31
ZA200108446B (en) 2003-08-27
HRP20010746A2 (en) 2002-10-31
SK14532001A3 (sk) 2002-02-05
WO2000062766A3 (en) 2002-10-31
EA200101089A1 (ru) 2002-10-31
TR200102977T2 (tr) 2002-09-23
NO20014950L (no) 2001-12-13
BG106104A (en) 2002-05-31
AU4583000A (en) 2000-11-02
YU77901A (sh) 2005-07-19
DK1274407T3 (da) 2006-06-26
CZ20013688A3 (cs) 2003-03-12
IL145875A0 (en) 2002-07-25
MA25351A1 (fr) 2001-12-31
EP1593379A2 (de) 2005-11-09
CA2370127A1 (en) 2000-10-26
EP1274407A2 (de) 2003-01-15
HK1053788A1 (zh) 2003-11-07
KR20010108506A (ko) 2001-12-07
DZ3151A1 (fr) 2000-10-19
ES2256003T3 (es) 2006-07-16
AP2001002291A0 (en) 2001-12-31
DE60026508T2 (de) 2006-11-16
BR0009776A (pt) 2002-06-04
HUP0300479A2 (hu) 2003-07-28
DE60026508D1 (de) 2006-05-04
CN1413105A (zh) 2003-04-23
PL364720A1 (en) 2004-12-13
WO2000062766A2 (en) 2000-10-26

Similar Documents

Publication Publication Date Title
FI20000863L (fi) Uusi hoitomenetelmä
DE60028849D1 (de) Sterilisationsmethode
DE69828821D1 (de) Wasserbehandlungsverfahren
DE60040607D1 (de) Wasserbehandlungseinrichtung
DE60041641D1 (de) Plasma behandlungsapparat
DE60017514D1 (de) Laserbehandlungsgerät
ID30025A (id) Metode perlakuan tekstil
DE60030210D1 (de) Elektrolytisches Behandlungsverfahren
NO20014950D0 (no) Nye behandlingsmetoder
DE60023454D1 (de) Lagenmaterialen mit tensid-modifizierten chelatbildern behandelt
NO20005179D0 (no) Medikament behandling
ATE269391T1 (de) Wäschebehandlung
DE69718808D1 (de) Plasmabehandlungsmethode
NO20013337L (no) Ny behandling
ID19542A (id) Pengobatan baru
NO20013596D0 (no) Slambehandling
DE60037935D1 (de) Kontinuierliches behandlungssystem
DE60022086D1 (de) Wasserbehandlung
ID25984A (id) Metode pengeringan cat-dasar
DE19883020T1 (de) Entladungsoberflächen-Behandlungsverfahren
DE69912763D1 (de) Behandlungsanlage
DK1135128T3 (da) Nye behandlingsfremgangsmåder
ID29042A (id) Metode pengobatan baru
ATA203199A (de) Ablauf
SE9903421D0 (sv) Behandlingsförfarande